Zoetis has received a license from the United States Department of Agriculture (USDA) for Cytopoint Plus, a new monoclonal antibody (mAb) for the treatment of allergic dermatitis in dogs.
According to Zoetis, the single-injection therapy targets and neutralizes interleukin-31 to provide 75 days of continuous allergic itch relief. This extends the dosing interval to approximately 1.5 times that of existing options, establishing it as the longest-acting licensed mAb available for canine allergic skin disease.
The extended duration is specifically designed to eliminate compliance barriers associated with chronic management. By reducing the frequency of required veterinary appointments, the therapy lowers the risk of missed doses and preventable flare-ups. Cytopoint Plus joins Zoetis’ existing canine dermatology portfolio, which includes the original Cytopoint (dosed every four to eight weeks) and the fast-acting oral therapy Apoquel.
“The license of Cytopoint Plus sets a new benchmark in canine dermatology,” said Abhay Nayak, executive vice president and president of U.S. commercial operations at Zoetis. “As a long-acting monoclonal antibody, Cytopoint Plus gives veterinary health professionals the ability to deliver reliable, sustained relief against allergic itch.”
Highlighting the operational benefits for practices and pet owners, Dr. Lindsay McKay of Animal Dermatology Group stated that frequent visits create scheduling hurdles, noting that the new formulation “directly addresses this challenge, extending the duration of relief from allergic itch through a manageable, convenient treatment routine.”